Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Astellas Pharma Inc. (YPH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
14.40-0.14 (-0.96%)
At close: 04:27PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.54
Open14.59
Bid14.36 x 80000
Ask14.61 x 70000
Day's Range14.40 - 14.59
52 Week Range13.15 - 15.62
Volume1,066
Avg. Volume166
Market Cap26.507B
Beta (5Y Monthly)0.55
PE Ratio (TTM)25.26
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.44 (3.02%)
Ex-Dividend DateMar 30, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for YPH.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • American City Business Journals

      Dallas-based Taysha Gene Therapies to receive $50M investment from Japanese pharmaceutical company

      The investment will go towards Taysha's adeno-associated virus gene therapy development programs for the treatment of Rett syndrome and giant axonal neuropathy.

    • Benzinga

      Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs

      Japan-based Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) announced a strategic investment to support the advancement of Taysha Gene Therapies Inc's (NASDAQ: TSHA) adeno-associated virus (AAV) gene therapy development programs for of Rett syndrome and Giant Axonal Neuropathy (GAN). In March this year, Taysha slashed 35% of its workforce and narrowed its R&D focus to extend its cash runway to Q4 of 2023. It also narrowed its focus to registration-directed gene therapy programs in GAN and Rett syn

    • Benzinga

      Astellas' Menopause Drug Under FDA Review

      The FDA accepted Astellas Pharma Inc's (OTC: ALPMF) menopause treatment for approval five months after the therapy hit a speed bump in a phase 3 trial conducted in Asia. With the FDA's acceptance of Astellas' marketing application for fezolinetant, the company expects a regulatory decision by February 22, 2023, following the use of a priority review voucher. The application is based on the results from the BRIGHT SKY program, which included three Phase 3 clinical trials that collectively enrolle

    Advertisement
    Advertisement